Complicating factors in safety testing of drug metabolites: Kinetic differences between generated and preformed metabolites

Toxicology and Applied Pharmacology

Volumn 217, Issue 2, 2006, Pages 143-152

  Prueksaritanont, Thomayant ^a   Lin, Jiunn H ^a   Baillie, Thomas A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Disposition; Drug metabolites; Preformed metabolites; Safety assessment

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ADEFOVIR; AGLYCONE; ATORVASTATIN; CIDOFOVIR; CIMETIDINE; DOPAMINE; DRUG METABOLITE; ENALAPRIL; ENALAPRILAT; FELBAMATE; GLUCURONIDE; GS 7340; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; LACTONE; LEVODOPA; METFORMIN; MEVINOLIN; MORPHINE; MRL 111; NUCLEOSIDE; NUCLEOSIDE ANALOG; NUCLEOTIDE; PARACETAMOL; PHENACETIN; PRAVASTATIN; SIMVASTATIN; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DIARRHEA; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVITY; HUMAN; HYPERTENSION; KINETICS; LACTIC ACIDOSIS; MEMBRANE PERMEABILITY; NEPHROTOXICITY; NONHUMAN; PARKINSON DISEASE; PHYSICAL CHEMISTRY; REVIEW; SCIENCE; TOXICOLOGY;

ANIMALS; BIOTRANSFORMATION; DRUG TOXICITY; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RISK ASSESSMENT; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 33751249069     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2006.08.009     Document Type: Review

References (97)

1. Abu-Zahra T.N., and Pang K.S. Effect of zonal transport and metabolism on hepatic removal: enalapril hydrolysis in zonal, isolated rat hepatocytes in vitro and correlation with perfusion data. Drug Metab. Dispos. 28 (2000) 807-813
2. Baillie T.A., Cayen M.N., Fouda H., Gerson R.J., Green J.D., Grossman S.J., Klunk L.J., LeBlanc B., Perkins D.C., and Shipley L.A. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182 (2002) 188-196
3. Baillie T.A., Cayen M.N., Fouda H., Gerson R.J., Green J.D., Grossman S.J., Klunk L.J., LeBlanc B., Perkins D.C., and Shipley L.A. Reply. Toxicol. Appl. Pharmacol. 190 (2003) 93-94
4. Bender R.P., Lindsey R.H., Burden D.A., and Osheroff N. N-acetyl-p-benzoquinone imine, the toxic metabolite of acetaminophen, is a topoisomerase II poison. Biochemistry 43 (2004) 3731-3739
5. Benet L.Z., Cummins C.L., and Wu C.Y. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm. 277 (2004) 3-9
6. Bourasset F., Cisternino S., Temsamani J., and Scherrmann J.-M. Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier. J. Neurochem. 86 (2003) 1564-1567
7. Cisternino S., Rousselle C., Debray M., and Scherrmann J.M. In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier. Pharm. Res. 21 (2004) 1382-1389
8. Chen C., Mireles R.J., Campbell S.D., Lin J., Mills J.B., Xu J.J., and Smolarek T.A. Differential interaction of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab. Dispos. 33 (2005) 537-546
9. Coughtrie M.W.H., Ask B., Rane A., Burchell B., and Hume R. The enantioselective glucuronidation of morphine in rats and humans. Biochem. Pharmacol. 19 (1989) 3273-3280
10. de Lannoy I.A.M., Nespeca R., and Pang K.S. Renal handling of enalapril and enalaprilat: studies in the isolated red blood cell-perfused rat kidney. J. Pharmacol. Exp. Ther. 251 (1989) 1211-1222
11. de Lannoy I.A.M., Baker F., and Pang K.S. Formed and preformed metabolite excretion clearances in liver, a metabolite formation organ: studies on enalapril and enalaprilat in the single-pass and recirculating perfused rat liver. J. Pharmacokinet. Biopharm. 21 (1993) 395-422
12. Dell D. Labile metabolites. Chromatographia 59 (2004) S139-S148 (Suppl.)
13. Dieckhaus C.M., Miller T.A., Sofia R.D., and Macdonald T.L. A mechanistic approach to understanding species differences in felbamate bioactivation: relevance to drug-induced idiosyncratic reactions. Drug Metab. Dispos. 28 (2000) 814-822
14. Ding X.X., and Kaminsky L.S. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 43 (2003) 149-173
15. Doherty M.M., and Pang K.S. Route-dependent metabolism of morphine in the vascularly perfused rat small intestine preparation. Pharm. Res. 17 (2000) 291-298
16. Doherty M.M., Poon I.M., Tsang C., and Pang K.S. Transport is not rate-limiting in morphine glucuronidation in the single-pass perfused rat liver preparation. J. Pharmacol. Exp. Ther. 317 (2006) 890-900
17. Du L.P., Hoffman S.M.G., and Keeney D.S. Epidermal CYP2 family cytochromes P450. Toxicol. Appl. Pharmacol. 195 (2004) 278-287
18. Evans A.M. Membrane transport as a determinant of the hepatic elimination of drugs and metabolites. Clin. Exp. Pharmacol. Physiol. 23 (1996) 970-974
19. Evans A.M., and Shanahan K. Biliary excretion of hepatically-generated and pre-formed morphine-3-glucuronide (M-3-G) in the isolated perfused rat liver: evidence for a diffusional barrier. Clin. Exp. Pharmacol. Physiol. 10 Suppl. 1 (1993) S22
20. Evans A.M., O'Brien J., and Nation R.L. Application of a loading wash-out method for investigating the hepatocellular efflux of a hepatically-generated metabolite morphine-3-glucuronide. J. Pharm. Pharmacol. 51 (1999) 1289-1297
21. Gamage N., Barnett A., Hempel N., Duggleby R.G., Windmill K.F., Martin J.L., and McManus M.E. Human sulfotransferases and their role in chemical metabolism. Toxicol. Sci. 90 (2006) 5-22
22. Gregory P.A., Lewinsky R.H., Gardner-Stephen D.A., and Mackenzie P.I. Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol Appl. Pharmacol. 199 (2004) 354-363
23. Hagenbuch B., and Meier P.J. The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta, Biomembr. 1609 (2003) 1-18
24. Haimeur A., Conseil G., Deeley R.G., and Cole S.P.C. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr. Drug Metab. 5 (2004) 21-53
25. Hastings K.L., El-Hage, Jacobs J.A., Leighton J., Morse D., and Osterberg R.E. Letter to the editor. Toxicol. Appl. Pharmacol. 190 (2003) 91-92
26. Hirano M., Maeda K., Shitara Y., and Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther. 311 (2004) 139-146
27. Ho E.S., Lin D.C., Mendel D.B., and Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J. Am. Soc. Nephrol. 11 (2000) 383-393
28. Hochman J.H., Pudvah N.T., Qiu Y., Yamazaki M., Tang C., Lin J.H., and Prueksaritanont T. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm. Res. 21 (2004) 1688-1693
29. Houston J.B. Drug metabolite kinetics. Pharmacol. Ther. 15 (1982) 521-552
30. Ito S., and Alcorn J. Xenobiotic transporter expression and function in the human mammary gland. Adv. Drug Deliv. Rev. 55 (2003) 653-665
31. Ishigami M., Honda T., Takasaki W., Ikeda T., Komai T., Ito K., and Sugiyama Y. A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab. Dispos. 29 (2001) 282-288
32. James L.P., Mayeux P.R., and Hinson J.A. Acetaminophen-induced hepatotoxicity. Drug. Metab. Dispos. 31 (2003) 1499-1506
33. Jonker J.W., Wagenaar F., Mol C.A., Buitelaar M., Koepsell H., Smit J.W., and Schinkel A.H. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol. Cell. Biol. 23 (2001) 7902-7908
34. Kadlubar F.F., Unruh L.E., Flammang T.J., Sparks D., Mitchum R.K., and Mulder G.J. Alterations urinary levels of the carcinogen, N-hydroxy-2-naphthylamine, and its N-glucuronide in the rat by control of urinary pH, inhibition of metabolic sulfation, and changes in biliary excretion. Chem.-Biol. Interact. 33 (1981) 129-147
35. Kiang T.K.L., Ensom M.H.H., and Chang T.K.H. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol. Ther. 106 (2005) 97-132
36. Koepsell H., and Endou H. The SLC22 drug transporter family. Eur. J. Physiol. 447 (2004) 666-676
37. Kothare P.A., and Zimmerman C.L. Intestinal metabolism: the role of enzyme localization in phenol metabolite kinetics. Drug. Metab. Dispos. 30 (2002) 586-594
38. Kruh G.D., and Belinsky M.G. The MRP family of drug efflux pumps. Oncogene 22 (2003) 7537-7552
39. Kuo C.K., Hanioka N., Hoshikawa Y., Oguri K., and Yoshimura H. Species difference of site-selective glucuronidation of morphine. J. Pharmacobio-Dyn. 14 (1991) 187-193
40. Kusuhara H., and Sugiyama Y. Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J. Control. Release 78 (2002) 43-54
41. Lee W.A., He G.X., Eisenberg E., Cihlar T., Swaminathan S., Mulato A., and Cundy K.C. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob. Chemother. 49 (2005) 1898-1906
42. Lin J.H. Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. 23 (1995) 1008-1021
43. Lin J.H. Tissue distribution and pharmacodynamics: a complicated relationship. Curr. Drug Metab. 7 (2006) 39-65
44. Liu L.C., and Pang K.S. The roles of transporters and enzymes in hepatic drug processing. Drug Metab. Dispos. 33 (2005) 1-9
45. Liu L.C., Mak E., Tirona R.G., Tan E., Novikoff P.M., Wang P., Wolkoff A., and Pang K.S. Vascular binding, blood flow, transporter, and enzyme interactions on the processing of digoxin in rat liver. J. Pharmacol. Exp. Ther. 315 (2005) 433-448
46. Liu L.C., Cui Y.H., Chung A.Y., Shitara Y., Sugiyama Y., Keppler D., and Pang K.S. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J. Pharmacol. Exp. Ther. 318 (2006) 395-402
47. Lo A., Addison R.S., Hooper W.D., and Dickenson R.G. Disposition of naproxen, naproxen acyl glucuronide and its rearrangement isomers in the isolated perfused rat liver. Xenobiotica 31 (2001) 309-319
48. Ma M.K., and McLeod H.L. Lessons learned from the irinotecan metabolic pathway. Curr. Med. Chem. 10 (2003) 41-49
49. Maher J.M., Slitt A.L., Cherrington N.J., Cheng X., and Klaassen C.D. Tissue distribution and hepatic and renal ontogeny of the multidrug resistance-associated protein (MRP) family in mice. Drug Metab. Dispos. 33 (2005) 947-955
50. Mathijssen R.H.J., van Alphen R.J., Verweij J., Loos W.J., Nooter K., Stoter G., and Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 7 (2001) 2182-2194
51. Miyauchi S., Sugiyama Y., Sato H., Sawada Y., Iga T., and Hanano M. Effects of a diffusional barrier to a metabolite across hepatocytes on its kinetics in "enzyme-distributed" model a computer-aided simulation study. J. Pharmacokinet. Biopharm. 15 (1987) 399-421
52. Mutlib A.E., Chen H., Nemeth G.A., Markwalder J.A., Seitz S.P., Gan L.S., and Christ D.D. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab. Dispos. 27 (1999) 1319-1333
53. Nagata Y., Kusuhara H., Endou H., and Sugiyama Y. Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol. Pharmacol. 61 (2002) 982-988
54. Nagano W., Yamada H., and Oguri K. Characteristic glucuronidation pattern of physiologic concentration of morphine in rat brain. Life Sci. 67 (2000) 2453-2464
55. Nutt J.G., Woodward W.R., Hammerstad J.P., Carter M.N., and Anderson J.L. The 'on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N. Engl. J. Med. 310 (1984) 483-488
56. Okura T., Saito M., Nakanishi M., Komiyama N., Fujii A., Yamada S., and Kimura R. Different distribution of morphine and morphine-6β-glucuronide after intracerebroventricular injection in rats. Br. J. Pharmacol. 140 (2003) 211-217
57. Pang K.S., and Gillette J.R. Kinetics of metabolite formation and elimination in the perfused rat liver preparation: differences between elimination of preformed acetaminophen and acetaminophen formed from phenacetin. J. Pharmacol. Exp. Ther. 207 (1978) 178-194
58. Pang K.S., and Terrell A. Conjugation kinetics of acetaminophen by the perfused rat-liver preparation. Biochem. Pharmacol. 30 (1981) 1959-1965
59. Pang K.S., Waller L., Horning M.G., and Chan K.K. Metabolite kinetics-formation of acetaminophen from dueterated and non-dueterated phenacetin and acetanilide on acetaminophen sulfation kinetics in the perfused-rat liver preparation. J. Pharmacol. Exp. Ther. 222 (1982) 14-19
60. Pang K.S., Cherry W.F., Terrell J.A., and Ulm E.H. Disposition of enalapril and its diacid metabolite, enalaprilat, in a perfused rat liver preparation. Presence of a diffusional barrier into hepatocytes. Drug Metab. Dispos. 12 (1984) 309-313
61. Pang K.S., Baker F., Cherry W.F., and Goresky C.A. Esterases for enalapril hydrolysis are concentrated in the perihepatic venous region of the rat-liver. J. Pharmacol. Exp. Ther. 257 (1991) 294-301
62. Pang K.S., Xin X., and Stpierre M.V. Determinants of metabolite disposition. Ann. Rev. Pharmacol. Toxicol. 32 (1992) 623-669
63. Pang K.S., Wang P.J., Chung A.Y.K., and Wolkoff A.W. The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology 28 (1998) 1341-1346
64. Pardridge W.M. Recent advances in blood-brain barrier transport. Annu. Rev. Pharmacol. Toxicol. 28 (1988) 25-39
65. Pastor-Anglada M., Cano-Soldado P., Molina-Arcas M., Pilar Lostaob M., Larráyozb I., Martínez-Picadoc J., and Casado F.J. Cell entry and export of nucleoside analogues. Virus Res. 107 (2005) 151-164
66. Pauwels R., Baba M., Balzarini J., Herdewijn P., Desmyter J., Robins M.J., Zou R., Madej D., and de Clercq E. Investigations on the anti-HIV activity of 2′3′-dideoxyadenosine analogs with modification in either the pentose or purine moiety-potent and selective anti-HIV activity of 2,6-diaminopurine 2′3′-dideoxyriboside. Biochem. Pharmacol. 37 (1988) 1317-1325
67. Prueksaritanont T., Subramanian R., Fang X., Ma B., Qiu Y., Lin J.H., Pearson P.G., and Baillie T.A. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab. Dispos. 30 (2002) 505-512
68. Regina A., Koman A., Piciotti M., El Hafny B., Center M.S., Bergmann R., Couraud P.O., and Roux F. Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J. Neurochem. 71 (1998) 705-715
69. Rowland M., and Tozer T.N. Clinical Pharmacokinetics: Concepts and Applications. 3rd ed. (1995), Lee and Febiger, New York
70. Sabordo L., Sallustio B.C., Evans A.M., and Nation R.L. Hepatic disposition of the acyl glucuronide1-O-gemfibrozil-β-d-glucuronide: effects of dibromosulfophthalein on membrane transport and aglycone formation. J. Pharmacol. Exp. Ther. 288 (1999) 414-420
71. Sallustio B.C., Fairchild B.A., Shanahan K., Evans A.M., and Nation R.L. Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. Drug Metab. Dispos. 24 (1996) 984-989
72. Sallustio B.C., Sabordo L., Evans A.M., and Nation R.L. Hepatic disposition of electrophilic acyl glucuronide conjugates. Curr. Drug Metab. 1 (2000) 163-180
73. Schinkel A.H., and Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55 (2003) 3-29
74. Schwab A.J., and Pang K.S. The multiple indicator-dilution method for the study of enzyme heterogeneity in liver: theoretical basis. Drug Metab. Dispos. 27 (1999) 746-755
75. Schwab A.J., Tao L., Kang M., Meng L., and Pang K.S. Moment analysis of metabolic heterogeneity: conjugation of benzoate with glycine in rat liver studied by multiple indicator dilution technique. J. Pharmacol. Exp. Ther. 305 (2003) 279-289
76. Serajuddin A.T., Ranadive S.A., and Mahoney E.M. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J. Pharma. Sci. 80 (1991) 830-834
77. Smith D.A., and Obach R.S. Seeing through the MIST: abundance versus percentage. Drug Metab. Dispos. 33 (2005) 1409-1417
78. Strazielle N., Khuth S.T., and Ghersi-Egea J.F. Detoxification systems, passive and specific transport for drugs at the blood-CSF barrier in normal and pathological situations. Adv. Drug Deliv. Rev. 56 (2004) 1717-1740
79. Tahara H., Kusuhara H., Endou H., Koepsell H., Imaoka T., Fuse E., and Sugiyama Y. A species difference in the transport activities of H-2 receptor antagonists by rat and human renal organic anion and cation transporters. J. Pharmacol. Exp. Ther. 315 (2005) 337-345
80. Tahara H., Shono M., Kusuhara H., Kinoshita H., Fuse E., Takadate A., Otagiri M., and Sugiyama Y. Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney. Pharm. Res. 22 (2005) 647-660
81. Tan E., Lu T., and Pang K.S. Futile cycling of estrone sulfate and estrone in the recirculating perfused rat liver preparation. J. Pharmacol. Exp. Ther. 297 (2001) 423-436
82. Their R., Wiebel F.A., Hinkel A., Burger A., Brüning T., Morgenroth K., Senge T., Wilhelm M., and Schulz T.G. Species differences in the glutathione transferase GSTT1-1 activity towards the model substrates methyl chloride and dichloromethane in liver and kidney. Arch. Toxicol. 72 (1998) 622-629
83. Tirona R.G., and Pang KS. Sequestered endoplasmic reticulum space for sequential metabolism of salicylamide-coupling of hydroxylation and glucuronidation. Drug Metab. Dispos. 24 (1996) 821-833
84. Urrea R., and Bronfman M. Species differences in the intracellular distribution of ciprofibroyl-CoA hydrolase. Implications for peroxisome proliferation. FEBS Lett. 389 (1996) 219-223
85. U.S. Food and Drug Administration, 2005. Draft Guidance for Industry on Safety Testing of Drug Metabolites. U.S. Food and Drug Administration, Center for Drug Evaluation and Research.
86. Vickers S., Duncan C.A., Chen I.-W., Rosegay A., and Duggan D.E. Metabolic disposition studies of simvastatin, a cholesterol-lowering prodrug. Drug Metab. Dispos. 18 (1990) 138-145
87. Wahlström A., Winblad B., Bixo M., and Rane A. Human brain metabolism of morphine and naloxone. Pain 35 (1998) 121-127
88. Wang M., and Dickinson R.G. Disposition and covalent binding of diflunisal and diflunisal acyl glucuronide in the isolated perfused rat liver. Drug Metab. Dispos. 26 (1998) 98-104
89. Wang M., Gorrell M.D., McCaughan G.W., and Dickenson R.G. Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac. Life Sci. 68 (2001) 785-797
90. Wang D.S., Kusuhara H., Kato Y., Jonker J.W., Schinkel A.H., and Sugiyama Y. Involvement of organic cation transporter 1 in the lactic acidosis caused bv metformin. Mol. Pharmacol. 63 (2003) 844-848
91. Watari N., Iwai M., and Kaneniwa N. Pharmacokinetic study of the fate of acetaminophen and its conjugates in rats. J. Pharmacokinet. Biopharm. 11 (1983) 245-272
92. Wright S.H., and Dantzler W.H. Molecular and cellular physiology of renal organic cation and anion transport. Physiol. Rev. 84 (2004) 987-1049
93. Wu D.F., Kang Y.S., Bickel U., and Pardridge W.M. Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. Drug Metab Dispos. 25 (1997) 768-771
94. Yamauchi A., Ueda N., Hanafusa S., Yamashita E., Kihara M., and Naito S. Tissue distribution of and species differences in deacetylation of N-acetyl-l-cysteine and immunohistochemical localization of acylase I in the primate kidney. J. Pharm. Pharmacol. 54 (2002) 205-212
95. Yamazaki M., Tokui T., Ishigami M., and Sugiyama Y. Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system. Biopharm. Drug Dispos. 17 (1996) 775-789
96. You G.F. The role of organic ion transporters in drug disposition: an update. Curr. Drug Metab. 5 (2004) 55-62
97. Zamek-Gliszczynski M.J., Hoffmaster K.A., Nezasa K., Tallman M.N., and Brouwer K.L.R. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur. J. Pharm. Sci. 27 (2006) 447-486